Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medical Developments International Ltd Lodges Marketing Authorisation in Europe


Monday, 14 Oct 2013 06:00pm EDT 

Medical Developments International Ltd announced that it has lodged its Marketing Authorisation Application (MAA) in Europe and that it has been accepted for review by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom. Once approved, Penthrox will be available for sale in the UK, France, Belgium and Ireland. The MAA contains MVP’s Regulatory Dossier which is the compilation of Clinical and Non-Clinical studies evidencing the safety and efficacy of Penthrox. 

Company Quote

2.29
0.06 +2.69%
27 Mar 2015